India, May 30 -- Pfizer Inc. (PFE) announced detailed results from the pivotal Phase 3 TALAPRO-3 study evaluating TALZENNA (talazoparib), an oral PARP inhibitor, in combination with XTANDI (enzalutamide), an androgen receptor pathway inhibitor, in men with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC).
The combination of TALZENNA plus XTANDI demonstrated a 52% reduction in the risk of radiographic progression or death compared to placebo plus XTANDI. At three years, radiographic progression-free survival (rPFS) rates were estimated at 77% for patients treated with TALZENNA plus XTANDI versus 56% for those treated...